You are here

generics

Lyrica looking grim: Pfizer blockbuster's market share crumbles under generic attack

Lyrica looking grim: Pfizer blockbuster's market share crumbles under generic attack

Fierce Pharma

Flag link:

Generic Drug Approvals Hit Another Record High as Competition, Quality Questions Linger

Generic Drug Approvals Hit Another Record High as Competition, Quality Questions Linger

RAPS.org

Flag link:

Sanofi defends top oncology drug with Jevtana patent win

Sanofi defends top oncology drug with Jevtana patent win

Fierce Pharma

Flag link:

3 generic drugmakers accused of 'stonewalling' congressional probe

3 generic drugmakers accused of 'stonewalling' congressional probe

Beckers Hospital Review

Teva Pharmaceutical

Heritage Pharmaceuticals

Flag link:

Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA

Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA

Fierce Pharma

Teva Pharmaceutical

Flag link:

What Enbrel needs to do after its patent win

What Enbrel needs to do after its patent win

EP Vantage

Flag link:

Enbrel ruling lifts Amgen shares

Enbrel ruling lifts Amgen shares

BioCentury

Flag link:

GAO Pushes FDA to Improve First Cycle Generic Approval Rate

GAO Pushes FDA to Improve First Cycle Generic Approval Rate

RAPS.org

Flag link:

Under a cloud of opioid lawsuits, Mallinckrodt suspends specialty generics spinoff

Under a cloud of opioid lawsuits, Mallinckrodt suspends specialty generics spinoff

Endpoints

Sonorant Therapeutics

Flag link:

Drugmakers master rolling out their own generics to stifle competition

Drugmakers master rolling out their own generics to stifle competition

Fierce Pharma

Hatch Waxman Act

Flag link:

Lyrica Patent Expiration Ushers In 9 Generic Competitors

Lyrica Patent Expiration Ushers In 9 Generic Competitors

Xtalks

Alembic Pharmaceuticals

Alkem Laboratories

MGN Laboratories

Rising Pharmaceuticals

Sciegen Pharmaceuticals

Teva Pharmaceutical

Flag link:

Opioid and price fixing legal liabilities mount for generic companies

Opioid and price fixing legal liabilities mount for generic companies

Biopharma Dive

Teva Pharmaceutical

Flag link:

Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts

Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts

Fierce Pharma

Flag link:

J&J warns generics will bite its pharma unit in the second half

J&J warns generics will bite its pharma unit in the second half

Pharmaforum

Flag link:

Why Isn’t Insulin a Complex Generic? PA Representative Asks FDA

Why Isn’t Insulin a Complex Generic? PA Representative Asks FDA

RAPS.org

Flag link:

Indivior loses appeal to block generic Suboxone opioid treatments

Indivior loses appeal to block generic Suboxone opioid treatments

Reuters

Flag link:

FDA Defends Generic Drug Approvals Despite Dip in June

FDA Defends Generic Drug Approvals Despite Dip in June

RAPS.org

Flag link:

The hits keep coming: Apotex loses 31 drug approvals after FDA cites plants for 'inadequate' controls

The hits keep coming: Apotex loses 31 drug approvals after FDA cites plants for 'inadequate' controls

Fierce Pharma

drug manufacturing

Flag link:

Supply constraints push EpiPen rival maker Amneal to restructure, shares fall

Supply constraints push EpiPen rival maker Amneal to restructure, shares fall

Endpoints

Flag link:

First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants

Drug Patent Watch

Flag link:

Pages